Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone treatment in children with Kabuki syndrome
NL-OMON39985Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somatropin in Kabuki syndrome and growth disorder, sponsored by Maastricht University Medical Center+. Primary endpoints: Increase in total energy expenditure during 6 weeks of rhGH treatment, Association between short-term TEE change and long-term height SDS change and 1 more. Started Apr 2013; status: recruiting.
02
Drugs
somatropin
03
Conditions
Kabuki syndromegrowth disorder
Beyond the preview
Go deeper on NL-OMON39985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39985.